Abstract
Background: Postoperative cerebral hyperperfusion syndrome (CHS) may occur after superficial temporal artery (STA)-middle cerebral artery (MCA) bypass for moyamoya disease (MMD). Predicting postoperative CHS is challenging; however, we previously reported the feasibility of using a hyperspectral camera (HSC) for monitoring intraoperative changes in brain surface hemodynamics during STA-MCA bypass. Objective: To investigate the utility of HSC to predict postoperative CHS during STA-MCA bypass for patients with MMD. Methods: Hyperspectral images of the cerebral cortex of 29 patients with MMD who underwent STA-MCA bypass were acquired by using an HSC before and after anastomosis. We then analyzed the changes in oxygen saturation after anastomosis and assessed its correlation with CHS. Results: Five patients experienced transient neurological deterioration several days after surgery. 123I-N-Isopropyl-iodoamphetamine single-photon emission computed tomography scan results revealed an intense, focal increase in cerebral blood flow at the site of anastomosis without any cerebral infarction. Patients with CHS showed significantly increased oxygen saturation (SO2) in the cerebral cortex after anastomosis relative to those without CHS (33 ± 28 vs. 8 ± 14%, p < 0.0001). Receiver operating characteristic analysis results show that postoperative CHS likely occurs when the increase rate of cortical SO2 value is >15% (sensitivity, 85.0%; specificity, 81.3%; area under curve, 0.871). Conclusions: This study indicates that hyperspectral imaging of the cerebral cortex may be used to predict postoperative CHS in patients with MMD undergoing STA-MCA bypass.
References
1.
Ishikawa
T
, Houkin
K
, Kamiyama
H
, Abe
H
. Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease
. Stroke
. 1997
;28
(6
):1170
–3
. .2.
Karasawa
J
, Touho
H
, Ohnishi
H
, Miyamoto
S
, Kikuchi
H
. Long-term follow-up study after extracranial-intracranial bypass surgery for anterior circulation ischemia in childhood moyamoya disease
. J Neurosurg
. 1992
;77
(1
):84
–9
. .3.
Miyamoto
S
, Akiyama
Y
, Nagata
I
, Karasawa
J
, Nozaki
K
, Hashimoto
N
, et al. Long-term outcome after STA-MCA anastomosis for moyamoya disease
. Neurosurg Focus
. 1998
;5
(5
):e5
. .4.
Miyamoto
S
, Yoshimoto
T
, Hashimoto
N
, Okada
Y
, Tsuji
I
, Tominaga
T
, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan adult moyamoya trial
. Stroke
. 2014
;45
(5
):1415
–21
. .5.
Fujimura
M
, Kaneta
T
, Mugikura
S
, Shimizu
H
, Tominaga
T
. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease
. Surg Neurol
. 2007
;67
(3
):273
–82
. .6.
Ogasawara
K
, Komoribayashi
N
, Kobayashi
M
, Fukuda
T
, Inoue
T
, Yamadate
K
, et al. Neural damage caused by cerebral hyperperfusion after arterial bypass surgery in a patient with moyamoya disease: case report
. Neurosurgery
. 2005
;56
(6
):E1380
–1
. .7.
Fujimura
M
, Shimizu
H
, Mugikura
S
, Tominaga
T
. Delayed intracerebral hemorrhage after superficial temporal artery-middle cerebral artery anastomosis in a patient with moyamoya disease: possible involvement of cerebral hyperperfusion and increased vascular permeability
. Surg Neurol
. 2009
;71
(2
):223
–7
. .8.
Mori
M
, Chiba
T
, Nakamizo
A
, Kumashiro
R
, Murata
M
, Akahoshi
T
, et al. Intraoperative visualization of cerebral oxygenation using hyperspectral image data: a two-dimensional mapping method
. Int J Comput Assist Radiol Surg
. 2014
;9
(6
):1059
–72
. .9.
Tominaga
T
, Suzuki
N
, Miyamoto
S
, Koizumi
A
, Kuroda
S
, Takahashi
JC
, et al. Recommendations for the management of moyamoya disease: a statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) [2nd edition]
. Surg Cereb Stroke
. 2018
;46
(1
):1
–24
. .10.
Kuroda
S
, Kamiyama
H
, Abe
H
, Houkin
K
, Isobe
M
, Mitsumori
K
. Acetazolamide test in detecting reduced cerebral perfusion reserve and predicting long-term prognosis in patients with internal carotid artery occlusion
. Neurosurgery
. 1993
;32
(6
):912
–9
. .11.
Fujimura
M
, Shimizu
H
, Inoue
T
, Mugikura
S
, Saito
A
, Tominaga
T
. Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-isopropyl-p-[(123)I]iodoamphetamine single-photon emission computed tomography
. Neurosurgery
. 2011
;68
(4
):957
–5
. .12.
Kaku
Y
, Iihara
K
, Nakajima
N
, Kataoka
H
, Fukuda
K
, Masuoka
J
, et al. Cerebral blood flow and metabolism of hyperperfusion after cerebral revascularization in patients with moyamoya disease
. J Cereb Blood Flow Metab
. 2012
;32
(11
):2066
–75
. .13.
Yanagihara
W
, Chida
K
, Kobayashi
M
, Kubo
Y
, Yoshida
K
, Terasaki
K
, et al. Impact of cerebral blood flow changes due to arterial bypass surgery on cognitive function in adult patients with symptomatic ischemic moyamoya disease
. J Neurosurg
. 2018
;131
(6
):1716
–24
. .14.
Uchino
H
, Kuroda
S
, Hirata
K
, Shiga
T
, Houkin
K
, Tamaki
N
. Predictors and clinical features of postoperative hyperperfusion after surgical revascularization for moyamoya disease: a serial single photon emission CT/positron emission tomography study
. Stroke
. 2012
;43
(10
):2610
–6
. .15.
Awano
T
, Sakatani
K
, Yokose
N
, Kondo
Y
, Igarashi
T
, Hoshino
T
, et al. Intraoperative EC-IC bypass blood flow assessment with indocyanine green angiography in moyamoya and non-moyamoya ischemic stroke
. World Neurosurg
. 2010
;73
(6
):668
–74
. .16.
Ishikawa
T
, Yamaguchi
K
, Kawashima
A
, Funatsu
T
, Eguchi
S
, Matsuoka
G
, et al. Predicting the occurrence of hemorrhagic cerebral hyperperfusion syndrome using regional cerebral blood flow after direct bypass surgery in patients with moyamoya disease
. World Neurosurg
. 2018
;119
:e750
–6
. .17.
Kameyama
M
, Fujimura
M
, Tashiro
R
, Sato
K
, Endo
H
, Niizuma
K
, et al. Significance of quantitative cerebral blood flow measurement in the acute stage after revascularization surgery for adult moyamoya disease: implication for the pathological threshold of local cerebral hyperperfusion
. Cerebrovasc Dis
. 2019
;48
(3–6
):217
–25
. .18.
Kazumata
K
, Uchino
H
, Tokairin
K
, Ito
M
, Shiga
T
, Osanai
T
, et al. Cerebral hyperperfusion syndrome after revascularization surgery in moyamoya disease: region-symptom mapping and estimating a critical threshold
. World Neurosurg
. 2018
;114
:e388
–95
. .19.
Nakagawa
A
, Fujimura
M
, Arafune
T
, Sakuma
I
, Tominaga
T
. Clinical implications of intraoperative infrared brain surface monitoring during superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease
. J Neurosurg
. 2009
;111
(6
):1158
–64
. .20.
Fujimura
M
, Inoue
T
, Shimizu
H
, Saito
A
, Mugikura
S
, Tominaga
T
. Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease
. Cerebrovasc Dis
. 2012
;33
(5
):436
–45
. .21.
Matano
F
, Murai
Y
, Mizunari
T
, Adachi
K
, Kobayashi
S
, Morita
A
. Intracerebral hemorrhage caused by cerebral hyperperfusion after superficial temporal artery to middle cerebral artery bypass for atherosclerotic occlusive cerebrovascular disease
. NMC Case Rep J
. 2017
;4
(1
):27
–32
. .22.
Fabelo
H
, Ortega
S
, Lazcano
R
, Madroñal
D
, Callicó
GM
, Juárez
E
, et al. An intraoperative visualization system using hyperspectral imaging to aid in brain tumor delineation
. Sensors
. 2018
;18
(2
):430
. .23.
Clancy
NT
, Saso
S
, Stoyanov
D
, Sauvage
V
, Corless
DJ
, Boyd
M
, et al. Multispectral imaging of organ viability during uterine transplantation surgery in rabbits and sheep
. J Biomed Opt
. 2016
;21
(10
):106006
. .24.
Zhang
Y
, Wirkert
SJ
, Iszatt
J
, Kenngott
H
, Wagner
M
, Mayer
B
, et al. Tissue classification for laparoscopic image understanding based on multispectral texture analysis
. J Med Imaging
. 2017
;4
(1
):015001
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
